secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007462
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination
--------------------------------------------------------------------------------

- Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.
- Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.
- HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.
- HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.
- Mark Winderlich appointed Chief Development Officer effective April 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/0001558370-24-007462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/hook-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer